190 related articles for article (PubMed ID: 12960593)
1. The radiation biology of radioimmunotherapy.
Dixon KL
Nucl Med Commun; 2003 Sep; 24(9):951-7. PubMed ID: 12960593
[TBL] [Abstract][Full Text] [Related]
2. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
[TBL] [Abstract][Full Text] [Related]
3. Potential and pitfalls of therapy with alpha-particles.
Welch MJ
J Nucl Med; 2005 Aug; 46(8):1254-5. PubMed ID: 16085579
[No Abstract] [Full Text] [Related]
4. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy. Progress, potential and problems.
Mather SJ; Britton KE
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):248-50. PubMed ID: 15640787
[No Abstract] [Full Text] [Related]
6. Outpatient administration of radiolabeled monoclonal antibodies.
Tuinstra N
Clin J Oncol Nurs; 2003; 7(1):106-8. PubMed ID: 12629945
[No Abstract] [Full Text] [Related]
7. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
8. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
[TBL] [Abstract][Full Text] [Related]
9. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
Breitz HB; Fisher DR; Wessels BW
J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
[TBL] [Abstract][Full Text] [Related]
10. Haematopoietic toxicity of radium-223 in patients with high skeletal tumour burden.
Miederer M; Thomas C; Beck J; Hampel C; Krieger C; Baqué PE; Helisch A; Schreckenberger M
Nuklearmedizin; 2015; 54(5):197-203. PubMed ID: 26392087
[TBL] [Abstract][Full Text] [Related]
11. Relevance of radiobiological concepts in radionuclide therapy of cancer.
Kumar C; Shetake N; Desai S; Kumar A; Samuel G; Pandey BN
Int J Radiat Biol; 2016; 92(4):173-86. PubMed ID: 26917443
[TBL] [Abstract][Full Text] [Related]
12. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
[TBL] [Abstract][Full Text] [Related]
13. [Alpha-radioimmunotherapy: a review of recent developments].
Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
[TBL] [Abstract][Full Text] [Related]
14. Patient dosimetry in radionuclide therapy: the whys and the wherefores.
Thierens HM; Monsieurs MA; Bacher K
Nucl Med Commun; 2005 Jul; 26(7):593-9. PubMed ID: 15942479
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy with alpha-particle emitting radionuclides.
Zalutsky MR; Pozzi OR
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.
Sgouros G; Hobbs R; Josefsson A
Curr Radiopharm; 2018; 11(3):209-214. PubMed ID: 29697036
[TBL] [Abstract][Full Text] [Related]
17. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin.
Breitz HB; Fisher DR; Goris ML; Knox S; Ratliff B; Murtha AD; Weiden PL
Cancer Biother Radiopharm; 1999 Oct; 14(5):381-95. PubMed ID: 10850323
[TBL] [Abstract][Full Text] [Related]
18. 186Re-HEDP for metastatic bone pain in breast cancer patients.
Lam MG; de Klerk JM; van Rijk PP
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
[TBL] [Abstract][Full Text] [Related]
19. Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
DeNardo GL; Schlom J; Buchsbaum DJ; Meredith RF; O'Donoghue JA; Sgouros G; Humm JL; DeNardo SJ
Cancer; 2002 Feb; 94(4 Suppl):1332-48. PubMed ID: 11877764
[TBL] [Abstract][Full Text] [Related]
20. 153Sm-EDTMP for bone pain palliation in skeletal metastases.
Maini CL; Bergomi S; Romano L; Sciuto R
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S171-8. PubMed ID: 15127241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]